These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1837713)

  • 21. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.
    Rosengren A; Wilhelmsen L; Eriksson E; Risberg B; Wedel H
    BMJ; 1990 Dec; 301(6763):1248-51. PubMed ID: 2148699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study.
    Cantin B; Gagnon F; Moorjani S; Després JP; Lamarche B; Lupien PJ; Dagenais GR
    J Am Coll Cardiol; 1998 Mar; 31(3):519-25. PubMed ID: 9502629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
    Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study.
    Berg K; Dahlén G; Christophersen B; Cook T; Kjekshus J; Pedersen T
    Clin Genet; 1997 Nov; 52(5):254-61. PubMed ID: 9520115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lipoprotein Lp(a): a risk factor for atherosclerosis].
    Gutiérrez Fuentes JA; Gutiérrez Yago JJ; Díez Monedero E; Alvarez Berceruelo J; Zamorano Curiel P; Tejerina Abanades L
    Med Clin (Barc); 1989 Nov; 93(15):565-7. PubMed ID: 2533645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up.
    Heinonen OP; Huttunen JK; Manninen V; Mänttäri M; Koskinen P; Tenkanen L; Frick MH
    J Intern Med; 1994 Jan; 235(1):41-9. PubMed ID: 8283158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
    Nestel PJ; Barnes EH; Tonkin AM; Simes J; Fournier M; White HD; Colquhoun DM; Blankenberg S; Sullivan DR
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2902-8. PubMed ID: 24092750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study.
    Klausen IC; Sjøl A; Hansen PS; Gerdes LU; Møller L; Lemming L; Schroll M; Faergeman O
    Atherosclerosis; 1997 Jul; 132(1):77-84. PubMed ID: 9247362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients.
    Cressman MD; Heyka RJ; Paganini EP; O'Neil J; Skibinski CI; Hoff HF
    Circulation; 1992 Aug; 86(2):475-82. PubMed ID: 1386292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein Lp(a) excess and coronary heart disease.
    Stein JH; Rosenson RS
    Arch Intern Med; 1997 Jun; 157(11):1170-6. PubMed ID: 9183227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease.
    Frohlich J; Dobiásová M; Adler L; Francis M
    Physiol Res; 2004; 53(5):481-6. PubMed ID: 15479125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. All-cause mortality and competing risks of fatal and nonfatal vascular events in the Italian longitudinal study on aging: impact of lipoprotein(a).
    Solfrizzi V; Colacicco AM; D'Introno A; Capurso C; Chirico M; Frisardi V; Cacciapaglia M; Vendemiale G; Capurso A; Panza F
    Rejuvenation Res; 2009 Dec; 12(6):395-402. PubMed ID: 20014954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall.
    Morishita R; Ishii J; Kusumi Y; Yamada S; Komai N; Ohishi M; Nomura M; Hishida H; Niihashi M; Mitsumata M
    J Atheroscler Thromb; 2009 Aug; 16(4):410-8. PubMed ID: 19672030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.